News

ANCA-associated vasculitis (AAV) patients with antibodies targeting the myeloperoxidase (MPO) protein have higher levels of immune-activating pieces of the C3 protein in their urine, and these are closely associated with measures of disease severity, a small study showed. “These fragments may serve as sensitive, [noninvasive] biomarkers for [kidney] immune…

Lung complications are common among adults with ANCA-associated vasculitis (AAV), affecting four in five individuals throughout their disease course, with some developing lasting damage, a study found. According to the new analysis of more than 1,000 patients in the U.S. and Canada, patterns of lung involvement differed between those…

Adults with ANCA-associated vasculitis (AAV) who test positive for antibodies against the myeloperoxidase (MPO) protein may face cardiovascular events sooner than those with antibodies against the proteinase-3 (PR3) protein, according to a new study. The French study analyzed data from 402 adults with AAV. While the overall proportion of…

Nasal administration of niclosamide, a medication used in certain regions for intestinal tapeworm infections, may help reduce ear, nose, and throat (ENT) symptoms in people with ANCA-associated vasculitis (AAV). In particular, benefits were seen among individuals with self-reactive antibodies against the proteinase 3 (PR3) protein — one of the…

People with ANCA-associated vasculitis (AAV) have a significantly higher risk of developing certain blood and solid-organ cancers, compared with those without the rare autoimmune disease, according to a large real-world study in the U.S. The study examined the medical records of more than 18,000 people with AAV and a…

Dupilumab, an approved medication for diseases marked by high levels of the immune cell eosinophils, may help ease symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA), according to a study reporting on three patients. The therapy, sold as Dupixent, helped control asthma and atopic dermatitis — two conditions…

People with active granulomatosis with polyangiitis (GPA), the most common type of ANCA-associated vasculitis (AAV), had significantly higher levels of a specific type of immune cell called peripheral helper T (Tph) cells in their blood, a study found. Higher levels of circulating Tph (cTph) cells were also significantly linked…

Amgen said it declined a U.S. Food and Drug Administration (FDA) request to voluntarily withdraw Tavneos (avacopan), an oral treatment approved for the most common forms of ANCA-associated vasculitis (AAV), from the U.S. market. The FDA made the request because of concerns about the integrity of clinical…

Children with ANCA-associated vasculitis (AAV) have higher numbers of two specific subsets of neutrophils, a type of immune cell implicated in AAV, that produce high levels of molecules linked to inflammation and other damaging processes, a small study showed. Notably, these overactive neutrophils appear to have difficulty processing glutamine,…

Following questions about the integrity of clinical trial data, regulators in Europe are taking a second look at Tavneos (avacopan), an oral therapy approved for ANCA-associated vasculitis (AAV). In a press release, the European Medicines Agency (EMA) announced that it “will now review all available data to…